{"analyses":[{"groupDescription":"Treatment comparison between the pexidartinib and placebo groups at Week 25","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment comparison analysis","nonInferiorityType":"OTHER","pValue":"0.0043","statisticalMethod":"Fisher's Exact Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.2","value":"62.5"},{"groupId":"OG001","spread":"2.9","value":"62.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.3","value":"13.0"},{"groupId":"OG001","spread":"2.6","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Week 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.1","value":"15.1"},{"groupId":"OG001","spread":"2.4","value":"6.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"title":"Week 25"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Range of motion (ROM) of the joint was assessed by a qualified, independent, and blinded or third-party assessors at the clinical site. Measurements were recorded in degrees. At baseline, the plane of movement with the smallest relative value (worst) was identified and this plane was used for evaluating the relative change of motion subsequently. Only the plane with the worst impaired ROM at baseline was selected for subsequent analyses.","dispersionType":"Standard Error","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks Placebo: Placebo capsule matching Pexidartinib capsule for oral administration.","id":"OG001","title":"Placebo Part 1"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Range of motion was assessed in the ITT population in participants where data were available.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 13, and Week 25","title":"Mean Change From Baseline For Range of Motion (ROM) Score in Participants Receiving Pexidartinib Compared With Those on Placebo Up to Week 25","type":"SECONDARY","unitOfMeasure":"degrees"}